UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 841

Sortiert nach

B cells in the pathogenesis of primary Sjögren syndrome

Nature reviews. Rheumatology, 2018-03, Vol.14 (3), p.133

2018

Link zum Volltext

Verfügbarkeit prüfen

Sjögren Syndrome‐associated lymphomas: an update on pathogenesis and management

British journal of haematology, 2015-02, Vol.168 (3), p.317-327

2015

Link zum Volltext

Verfügbarkeit prüfen

Current and future therapies for primary Sjögren syndrome

Nature reviews. Rheumatology, 2021-08, Vol.17 (8), p.475

2021

Link zum Volltext

Verfügbarkeit prüfen

Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma

Rheumatology (Oxford, England), 2021-08, Vol.60 (8), p.3513-3521

2021

Link zum Volltext

Verfügbarkeit prüfen

Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications

Annals of the rheumatic diseases, 2020-03, Vol.79 (3), p.309

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune-related adverse events of checkpoint inhibitors

Nature reviews. Disease primers, 2020-05, Vol.6 (1), p.38-38, Article 38

2020

Link zum Volltext

Verfügbarkeit prüfen

Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study

Annals of the rheumatic diseases, 2018-02, Vol.77 (2), p.228

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Annals of the rheumatic diseases, 2017-07, Vol.76 (7), p.1253

2017

Link zum Volltext

Verfügbarkeit prüfen

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment

Annals of the rheumatic diseases, 2017-10, Vol.76 (10), p.1747

2017

Link zum Volltext

Verfügbarkeit prüfen

Monocyte/Macrophage Abnormalities Specific to Rheumatoid Arthritis Are Linked to miR-155 and Are Differentially Modulated by Different TNF Inhibitors

The Journal of immunology (1950), 2019-10, Vol.203 (7), p.1766-1775

2019

Link zum Volltext

Verfügbarkeit prüfen

EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome

Annals of the rheumatic diseases, 2010-06, Vol.69 (6), p.1103-1109

2010

Link zum Volltext

Verfügbarkeit prüfen

Interferon signature in systemic autoimmune diseases: what does it mean?

Rheumatic & musculoskeletal diseases open, 2022-12, Vol.8 (2), p.e002687

2022

Link zum Volltext

Verfügbarkeit prüfen

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

Annals of the Rheumatic Diseases, 2016-06, Vol.75 (6), p.952-957

2016

Link zum Volltext

Verfügbarkeit prüfen

Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements

Rheumatology (Oxford, England), 2015-12, Vol.54 (12), p.2230-2238

2015

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

Journal of clinical oncology, 2009-04, Vol.27 (10), p.1564-1571

2009

Link zum Volltext

Verfügbarkeit prüfen

Role of good oral hygiene on clinical evolution of rheumatoid arthritis: a randomized study nested in the ESPOIR cohort

Rheumatology, 2020-05, Vol.59 (5), p.988-996

2020

Link zum Volltext

Verfügbarkeit prüfen

Immune interventions in COVID-19: a matter of time?

Mucosal immunology, 2022-02, Vol.15 (2), p.198-210

2022

Link zum Volltext

Verfügbarkeit prüfen

Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation

Journal of allergy and clinical immunology, 2016-06, Vol.137 (6), p.1809-1821.e12

2016

Link zum Volltext

Verfügbarkeit prüfen

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

Annals of the rheumatic diseases, 2020-01, Vol.79 (1), p.88

2020

Link zum Volltext

Verfügbarkeit prüfen

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program

Arthritis care & research (2010), 2018-05, Vol.70 (5), p.685-694

2018

Link zum Volltext

Verfügbarkeit prüfen

Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?

Annals of the rheumatic diseases, 2019-06, Vol.78 (6), p.e46

2019

Link zum Volltext

Verfügbarkeit prüfen

JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis

Cellular & molecular immunology, 2020-05, Vol.17 (5), p.552-553

2020

Link zum Volltext

Verfügbarkeit prüfen

EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome

Annals of the rheumatic diseases, 2011-06, Vol.70 (6), p.968-972

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 841

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(718)
Mit Volltextzugriff
(737)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(547)
Life Sciences & Biomedicine
(533)
Humans
(460)
Rheumatology
(357)
Female
(271)
Life Sciences
(253)
Middle Aged
(249)
Male
(244)
Adult
(193)
Aged
(175)
Rheumatoid Arthritis
(163)
Treatment Outcome
(113)
Human Health And Pathology
(107)
Immunology
(101)
Patients
(99)
Biological And Medical Sciences
(97)
Arthritis, Rheumatoid - Drug Therapy
(96)
Medical Sciences
(96)
Antirheumatic Agents - Therapeutic Use
(83)
Rhumatology And Musculoskeletal System
(68)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

B cells in the pathogenesis of primary Sjögren syndrome

Sjögren Syndrome‐associated lymphomas: an update on pathogenesis and management

Current and future therapies for primary Sjögren syndrome

Lymphomas complicating primary Sjögren's syndrome: from autoimmunity to lymphoma

Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications

Immune-related adverse events of checkpoint inhibitors

Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment

Monocyte/Macrophage Abnormalities Specific to Rheumatoid Arthritis Are Linked to miR-155 and Are Differentially Modulated by Different TNF Inhibitors

EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome

Interferon signature in systemic autoimmune diseases: what does it mean?

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements

Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

Role of good oral hygiene on clinical evolution of rheumatoid arthritis: a randomized study nested in the ESPOIR cohort

Immune interventions in COVID-19: a matter of time?

Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation

Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program

Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?

JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis

Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort

EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome

Suchergebnisse filtern